drug manufacturers, glaxosmithkline, pfizer, johnson & johnson,

PR Newswire Drug Manufacturers, GlaxoSmithKline, Pfizer, Johnson & Johnson,
June 18, 2001

NEW YORK, June 18 /PRNewswire/ -- Strategic Research Institute New York announces its Multicultural Pharmaceutical Marketing & PR conference on June 25-26, 2001 in Princeton, New Jersey. The program features major companies like Pfizer, GlaxoSmithKline, Johnson & Johnson who will discuss their growing interest in marketing to multicultural populations. Dr. Jeff Humphreys, Selig Center for Economic Growth will open the conference with an updated analysis of the "buying power of minority populations" in the 21st century. At this conference, marketers will meet several leading experts in multicultural marketing and also meet with media representatives. The luncheon on June 25th is being sponsored by Spanish radio supremo, Radio Unica. For details visit http://www.srinstitute.com/cm350 or send email to rranganathan@srinstitute.com. Phones 1-212-967-0095x252. Cancer, Cardiovascular Disease, Diabetes, HIV/AIDS affect many minority populations disproportionately and drug marketers need to look at the many ethnic media channels, direct marketing tools and customer relationship building tools that are successfully employed by other industries. With the sweeping demographic changes that are taking place, it has become imperative for pharmaceutical companies to invest in multicultural marketing and community relationship building strategies. Companies in attendance, include, Prevention, Reader's Digest, HealthQuest, Univision, Eli Lilly, Imada Wong Communications Group and more. Contact Rupa Ranganathan, Ethnic Strategist at 212-967-0095, ext. 252 or call 800-599-4950, ext. 252 or e-mail rranganathan@srinstitute.com. SOURCE Strategic Research Institute Web Site: http://www.srinstitute.com/cm350

Most Read: Latest Added Related Topics White House LGBT Conference on HIV/AIDS UNITED STATES: White House in Atlanta: LGBT AIDS Conference No more single-theme conferences: global HIV prevention conference planned FHI 360 Senior Scientist Lut Van Damme Receives International Microbicide Conference Lifetime Achievement Award Equatorial Guinea Ministry of Health and Social Welfare and UNICEF Refute Erroneous AIDS Prevalence Figures Photographs from A Day with HIV Now Online Bulgaria urges Libya to investigate AIDS nurses case Engineers enter fight against AIDS in Africa Gilead’s Complera® Non-Inferior to Atripla® Among Treatment-Naive HIV Patients UN chief Ban calls world leaders to end Aids by 2020 Positive living Lawyer: NY man at center of HIV scare not positive Zimbabwe activist: Prisoners denied AIDS drugs Youth organizations form a pact for social transformation in the AIDS response CountyCare Offers Historic Opportunity to Improve Care for People with HIV International AIDS Advocates Demand China Give $1 Billion to Global Fund Kingdom of Bahrain and UNAIDS commit to intensify cooperation CANADA: Celibate Homosexual Men Now Allowed to Donate Blood in Canada AFRICA: UN: AIDS Deaths Down, Treatment Up in Africa MICHIGAN: STD Fee for Jackson County Walk-In Clinic Takes Effect June 3 Zimbabwe activist: Prisoners denied AIDS drugs Blue Cross To Allow HIV/AIDS Patients to "Opt-Out" of Mandatory Mail-Order Rx Drug Program, Announces Consumer Watchdog Study Finds Vitamin C Can Kill Drug-Resistant TB Immune system cancer drugs tipped to be a $35 billion market NEW JERSEY: Drug Company Donates Thousands to HIV/AIDS Orgs NORTH KOREA: North Korea Sees Surge of Drug-Resistant Tuberculosis Experimental Gilead drug effective in early-stage leukemia trial Public Meeting on HIV Patient-Focused Drug Development and HIV Cure Research: June 14, 2013 India's Largest Generic Drugmaker Ranbaxy Pays $500 Million to Settle Systemic Generic Drug Manufacturing Fraud AHF Shareholder Advocates Challenge Gilead on Drug Pricing at AGM
Copyright © 2001 -PR Newswire, Publisher. All rights reserved to PR Newswire.. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through PR Newswire, Permissions, 810 Seventh Ave., 32nd Floor, New York, NY 10019. Information in this article was accurate in June 18, 2001. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.